Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
Xiang-Yu ZhaoQian JiangHao JiangLi-Juan HuTing ZhaoXing-Xing YuXiao-Jun HuangPublished in: European journal of immunology (2020)
Clinical-grade mbIL-21/4-1BBL-expanded NK cells exhibited antileukemic activity against AML in vitro and in vivo.